Conditions: Breast Cancer Lung Cancer Colon Cancer Pancreatic Cancer Head and Neck Cancer Kidney Cancer Sarcoma Hepatocellular Cancer
Keywords: Solid tumor malignancy breast cancer lung cancer colon cancer pancreatic cancer head and neck cancer kidney cancer sarcoma hepatocellular cancer
Allocation: NON_RANDOMIZED | Intervention model: SEQUENTIAL
Enrollment: 31
Healthy volunteers: no

Brief summary:
This is a Phase I study; dose escalating the combination of pazopanib when taken daily and ixabepilone when administered on day 1 of a 3 week treatment course.

Detailed description:
Treatment with ixabepilone will be given at an assigned dose as a 3 hour intravenous infusion on day 1 of a 21 day cycle. Treatment with pazopanib will be given at an assigned dose by mouth once a day, beginning on day 1 and continuing daily. Disease assessment will be done every 2 cycles (6 weeks) with treatment continuing until disease progression, unacceptable toxicity or patient refusal.

Arms:
arm 1: Patient receives assigned dose level:

Dose Level 1 = 400 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 2 = 400 milligrams (mg) of pazopanib and ixabepilone 40 mg/m2. Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. Dose Level 4 = 800 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2. arm 2: Dose Level 3 = 600 milligrams (mg) of pazopanib and ixabepilone 32 mg/m2.

Interventions: intervention 1: Pazopanib intervention 2: Ixabepilone
Intervention descriptions: intervention 1: Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing. intervention 2: Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle

Protocol document: